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Real-Time Nucleic Acid Sequence-Based Amplification to Predict 
the Clinical Outcome of Invasive Aspergillosis
Monitoring the response to therapy for invasive aspergillosis (IA) is essential for the 
management of patients with hematologic diseases. We evaluated the correlation between 
the outcome of real-time nucleic acid sequence-based amplification (RTi-NASBA) for 
Aspergillus 18S rRNA and the clinical outcome of IA. A total of 157 serum samples from  
29 patients with IA were tested for RTi-NASBA. The treatment response and mortality were 
compared with the NASBA outcome (whether the NASBA value was converted to negative 
or not) at 12 weeks after the start of antifungal therapy. At 12 weeks, there was a 
moderate correlation between the treatment failure and persistently positive NASBA 
(κ = 0.482; P = 0.019). Deaths attributable to IA were more prevalent in patients without 
negative conversion of NASBA than in those with negative conversion (50% vs 5%; 
P = 0.013). Significant factors of treatment failure at 12 weeks were the status of 
hematologic disease (nonremission; P = 0.041) and the NASBA outcome (failure of 
negative conversion; P = 0.024). Survival was significantly better in patients with negative 
conversion of NASBA than those with persistently positive values (P = 0.036). This study 
suggests that the serial monitoring of RTi-NASBA could be useful for prediction of the 
clinical outcome in hematologic patients with IA.
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INTRODUCTION
Aspergillus is the most common filamentous fungal pathogen 
in febrile neutropenic patients with hematologic diseases or in 
recipients of hematopoietic stem cell transplantation (HSCT) 
(1, 2). In these patients, invasive aspergillosis (IA) has contrib-
uted to high morbidity and mortality rates despite current avail-
ability of new antifungal agents (3, 4).
  Diagnostic techniques, based on detection of either the anti-
gen (e.g. serum galactomannan by enzyme immunosorbent as-
say [GM-EIA] and (1→3)-β-D-glucan assay) or the nucleic acid 
(e.g. PCR), could be used for early detection of the Aspergillus 
species. However, false-negative results of GM-EIA have been 
reported in patients with exposure to a mold-active antifungal 
agent (5, 6). It has also been demonstrated that high-resolution 
computed tomography also plays a limited role, particularly 
during the early period of antifungal therapy (7, 8). Therefore, we 
need another proper surrogate marker to monitor the therapeu-
tic response and to predict the clinical outcome of IA.
  Nucleic acid sequence-based amplification (NASBA) was de-
veloped as a diagnostic method to detect target mRNA in an iso-
thermal amplification process. Unlike PCR to detect DNA, the 
detection of mRNA means the presence of viable fungal organ-
isms and highly-expressed genes can be used to assess the via-
bility of the infecting fungal organisms following antifungal ther-
apy (9). Also, an isothermal process could have less chance of 
contamination than the PCR process using thermal cycling. We 
have devised real-time NASBA (RTi-NASBA) using molecular 
beacon and applied this technique for the diagnosis of IA in pa-
tients with febrile neutropenia (10-12). Recently, we have tried 
a new paradigm of RTi-NASBA on the platform of the LightCy-
cler 480 system (13). However, there has been little knowledge 
about the practical usefulness of NASBA for evaluation of the 
treatment response to antifungal therapy in patients suffering 
from IA.
  In this study, we investigated the role of RTi-NASBA for Asper-
gillus spp. as a predictor of the treatment response and clinical 
outcome of IA in patients with hematologic disease.
 
MATERIALS AND METHODS
Patients
Between October 2008 and August 2009, we retrospectively iden-
tified the consecutive patients suspected of IA at the Catholic 
Bone Marrow Transplantation Center, Seoul, Korea. All episodes 
of possible, probable, or proven IA were included, as defined by Kim S-H, et al.  •  RTi-NASBA and Clinical Outcome of IA
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the revised definitions of the invasive fungal disease published 
by the European Organization for Research and Treatment of 
Cancer/Invasive Fungal Infections Cooperative Group and the 
National Institute of Allergy and Infectious Diseases Mycoses 
Study Group Consensus Group (14). Finally, we enrolled the pa-
tients with at least 3 serial, available serum specimens to moni-
tor the results of RTi-NASBA for the Aspergillus spp. during the 
period at risk for IA. Serum samples were usually obtained at 3 
to 7-day intervals and stored at -70°C immediately after the col-
lections. Patients under 15 yr of age were excluded.
  Patients with prolonged neutropenia (absolute neutrophil 
count of  < 500/μL for  > 10 days) received antimicrobial prophy-
laxis (ciprofloxacin [500 mg/day, p.o.] + fluconazole [100 mg/day, 
p.o.] or itraconazole oral solution [5 mg/kg/day]). All patients with 
neutropenia or other risk factors for IA were routinely screened 
twice weekly for GM-EIA (Platelia Aspergillus, Bio-Rad, Marnes-
la-Cocquette, France). GM-EIA value of  ≥ 0.5 was regarded as 
positive. The empirical antibiotic therapy was administered to 
the neutropenic patients at the onset of fever and then modified 
promptly according to the Infectious Diseases Society of Amer-
ica guidelines (15). The antifungal therapy was initiated empiri-
cally in patients presenting with persistent neutropenic fever af-
ter 5 days of antibiotic therapy or with any symptoms, signs, ra-
diographic or laboratory evidence of IA. We reviewed the medi-
cal records and collected the following data: demographic data, 
underlying disease, symptoms and signs related to IA, radio-
graphic and laboratory findings, and administration of antifun-
gal therapy.
Performance of NASBA
We performed quantitative RTi-NASBA targeting a highly con-
served region of Aspergillus 18S rRNA (verified by clinically rel-
evant Aspergillus spp. [A. fumigatus, A. flavus, A. niger, and A. 
terreus]) in serum samples as described in previous studies (10, 
11). The sequence of Asp 1.2 (including the T7-promoter se-
quence; underlined) was 5´-AATTCTAATACGACTCACTATAG-
GGGAGCAAAGGCCTGCTTTGAACA-3´, and that of Asp 2.1 
was: 5´-GCCGCGGTAATTCCAGCTCCAATA-3´. The sequence 
of molecular beacon was 5´-FAM-CGATCGGGTCCGCCTCAC-
CGCGAGTACTGCGATCG-DABCYL-3´. NASBA was primarily 
performed using the Nuclisense Basic Kit (BioMérieux Korea, 
Seoul, Korea) and monitored in real-time with the LightCycler 
480 system (Roche, Mannheim, Germany). The cut-off value of 
NASBA was determined at 1.571 times the mean of the negative 
control values as described previously (13). The time to positivity 
(TTP) was defined as the time at which the target and internal 
control amplification curves passed the cut-off values. RNA cop-
ies of Aspergillus spp. were calculated from the following regres-
sion equation (16):
  TTP  =  -2.2415  ×  Ln(copies) + 61.534
Outcome definitions
The study patients were divided into 2 groups based on the 
NASBA outcome, namely “NASBA success” and “NASBA fail-
ure” . The NASBA outcome was determined as one of the follow-
ing four patterns: overall negative, maintenance of negative con-
version, rebounding after transient negative, and persistently 
positive. Of these four, the first and the second patterns were 
defined as “NASBA success” , while the third and the fourth pat-
terns were assigned as “NASBA failure” . The treatment response 
and mortality were assessed at 12 weeks after the start of sys-
temic antifungal therapy. The treatment response was catego-
rized into 4 groups according to clinical, radiological, and my-
cological criteria as follows: complete, partial, stable response, 
and progression of fungal disease (17). Among these categories, 
the complete and partial responses were defined as “treatment 
success” and the other two as “treatment failure” . Death during 
the study period was considered as “failure” , regardless of attri-
bution. Death from an apparent primary cause unrelated to IA 
was excluded from the mortality rate attributable to IA. The fol-
low-up duration was calculated from the start date of systemic 
antifungal therapy to the date of the last follow-up or until death 
from any cause.
Statistical analysis
Categorical variables were compared using the Fisher’s exact test. 
The correlation between the NASBA outcome and the treatment 
response was measured using the kappa coefficient (κ). The sta-
tistical concordance was interpreted as follows: κ ≤ 0.2 was con-
sidered as slight, 0.2 < κ ≤ 0.4 as fair, 0.4 < κ ≤ 0.6 as moderate, 
0.6 < κ ≤ 0.8 as substantial and κ > 0.8 as almost perfect (18). Cox 
regression analysis was performed to assess the predictive value 
of NASBA for treatment failure at 12 weeks. The cumulative sur-
vival was estimated by the Kaplan-Meier method and the log-
rank test was used to compare the difference between the NASBA 
success and failure groups. The two-sided P values of  < 0.05 were 
considered statistically significant.
Ethics statement
This study was approved by the institutional review board of 
Yeouido St. Mary’s Hospital, the Catholic University of Korea 
(SC10SISI0012). Informed consent was exempted by the board 
due to the retrospective design. 
RESULTS
Characteristics of the study population
Of 41 patients with suspected IA, 29 patients were finally enrolled. 
The demographic characteristics and clinical features of the en-
rolled patients are summarized in Table 1. Aspergillus spp. (2 A. 
fumigatus and 1 A. flavus) were isolated from lung tissue or spu-
tum in only 3 patients. GM-EIA was positive at least once in 21 Kim S-H, et al.  •  RTi-NASBA and Clinical Outcome of IA
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patients. The first-line antifungal agent consisted of amphoteri-
cin B deoxycholate (n = 22), intravenous itraconazole (n = 5), or 
liposomal amphotericin B (n = 2). The median duration of intra-
venous and total antifungal therapy was 20 days (range, 3-102) 
and 77 days (range, 19-214), respectively. The median follow-up 
duration was 145 days (range, 29-225).
NASBA
A total of 157 serum samples were collected from 29 patients. 
The median number of tested samples per patient was 5 (range, 
4-9). The overall positivity of NASBA was 27% (42/157). Of 29 pa-
tients, 23 (79%) had at least one positive result of NASBA. Thir-
teen patients (45%) had at least 2 positive results of NASBA and 
the median frequency of the positive NASBA was 2 (range, 1-4) 
per patient. The Aspergillus RNA titers ranged from 1 to 59,541 
copies/mL. The median peak value of NASBA was higher in the 
NASBA failure group (2,303 copies/mL [range, 7-45,959]) than 
in the NASBA success group (91 copies/mL [range, 1-59,541]; 
P = 0.093). The median duration of persistently positive NASBA 
was 10 days (range, 1-37) in the NASBA failure group and 7 days 
(range, 2-23) in the NASBA success group, respectively (P = 0.548).
NASBA and clinical outcome
The NASBA outcome was as follows: overall negative (n = 6), 
maintenance of negative conversion (n = 15), rebounding after 
transient negative (n = 3), and persistently positive (n = 5). As 
the final outcome based on the NASBA results, NASBA success 
and NASBA failure were 21 and 8, respectively.
  Table 2 shows the treatment response and the clinical outcome 
at 12 weeks according to the NASBA outcome. A moderate cor-
relation was found between the NASBA outcome and the treat-
ment response (κ = 0.482; positive predictive value, 63%; nega-
tive predictive value, 86%; P = 0.019). Treatment failure was sig-
nificantly more prevalent in the NASBA failure group than in the 
NASBA success group (63% [5/8] vs 14% [3/21]; odds ratio [OR], 
10.0; 95% confidence interval [CI], 1.523-65.679). All 8 patients 
Table 1. Demographic and clinical characteristics of 29 patients with invasive asper-
gillosis
Characteristics No. (%) of patients
Age, yr, median (range) 49 (15-79)
Male sex 15 (52)
Underlying hematologic disease
   Diagnosis
      Acute myeloid leukemia
      Acute lymphocytic leukemia
      Myelodysplastic syndrome
      Severe aplastic anemia
      Others*
   Treatment
      Chemotherapy
      Hematopoietic stem cell transplantation
      Conservative treatment
   Status, complete remission
 
 
15 (52)
  5 (17)
  3 (10)
  3 (10)
  3 (10)
 
18 (62)
  5 (17)
  6 (21)
17 (59)
Invasive aspergillosis
   Risk factor
      Neutropenia
      Graft-versus-host disease
      Glucocorticoid use
      Uncontrolled leukemia
   Category
      Proven
      Probable
      Possible
   Organ
      Pulmonary
      Extrapulmonary
 
 
21 (72)
  3 (10)
  3 (10)
2 (7)
 
2 (7)
21 (72)
  6 (21)
 
24 (83)
  5 (17)
Duration of neutropenia, days, median (range) 30 (9-141)
Total number of NASBA tests per patient, median (range)    5 (4-9)
Mortality at 12 weeks   8 (28)
*Included multiple myeloma (n = 2) and chronic lymphocytic leukemia (n = 1). NASBA, 
nucleic acid sequence-based amplification.
Table 2. Treatment responses at 12 weeks according to the nucleic acid sequence-
based amplification outcome
No. (%) of patients
NASBA success 
(n = 21)
NASBA failure  
(n = 8)
Success
   Complete response
   Partial response
18 (86)
10
  8
3 (37)
2
1
Failure
   Stable response
   Progression
   Death
3 (14)
-
-
  3
5 (63)
-
-
5
NASBA, nucleic acid sequence-based amplification. 
Table 3. Clinical characteristics and causes of death of 8 patients who died within 12 weeks
No.
NASBA  
outcome
Sex
Age  
(yr)
Hematologic disease Invasive aspergillosis Antifungal therapy
Cause of death
Dx Tx Category Organ First-line Second-line
1 Success M 38 AML HSCT Probable Pulmonary cAMB Voriconazole Acute GVHD
2 Success F 62 ALL CTx Probable Pulmonary cAMB Voriconazole Massive hemoptysis
3 Success M 38 SAA Conservative Probable Pulmonary Itraconazole Voriconazole Progression of IA
4 Failure M 39 AML CTx Probable Pulmonary cAMB LAMB Uncontrolled leukemia
5 Failure F 48 SAA Conservative Probable Extrapulmonary cAMB Voriconazole Progression of IA
6 Failure M 79 CLL CTx Probable Pulmonary cAMB LAMB Progression of IA
7 Failure M 28 AML CTx Probable Pulmonary cAMB Caspofungin Progression of IA
8 Failure M 50 ALL CTx Probable Pulmonary cAMB Voriconazole Progression of IA
NASBA, nucleic acid sequence-based amplification; M, male; AML, acute myeloid leukemia; HSCT, hematopoietic stem cell transplantation; cAMB, amphotericin B deoxycho-
late; GVHD, graft-versus-host disease; F, female, ALL, acute lymphocytic leukemia; CTx, chemotherapy; SAA, severe aplastic anemia; IA, invasive aspergillosis; LAMB, liposomal 
amphotericin B; CLL, chronic lymphocytic leukemia; IA, invasive aspergillosis.Kim S-H, et al.  •  RTi-NASBA and Clinical Outcome of IA
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who showed treatment failure had died within 12 weeks (Table 
3). The causes of death included progression of IA (n = 5), refrac-
tory acute graft-versus-host disease (GVHD) (n = 1), massive 
hemoptysis related to invasive pulmonary aspergillosis (n = 1), 
and uncontrolled leukemia (n = 1). Among these, refractory acute 
GVHD, massive hemoptysis, and uncontrolled leukemia were 
excluded from the cause of death attributed to IA. The mortality 
rate attributable to IA was significantly higher in the NASBA fail-
ure group than in the NASBA success group (50% [4/8] vs 5% 
[1/21]; OR, 20.0; 95% CI, 1.743-229.492; κ = 0.512).
  In the Cox regression analysis, significant predictors of the 
treatment failure at 12 weeks were the status of hematologic dis-
ease (i.e. non-remission) and the NASBA outcome (i.e. NASBA 
failure) (Table 4). The median survival duration was 152 days 
(95% CI, 111-167) in the NASBA success group and 69 days (95% 
CI, 41-144) in the NASBA failure group, respectively. The surviv-
al rate of patients in the NASBA success group was significantly 
higher than that in the NASBA failure group (Fig. 1).
 
DISCUSSION
In this study, we investigated whether the serial monitoring of 
RTi-NASBA could predict the treatment response and clinical 
outcome of IA in patients with hematologic diseases. There is a 
lack of the sensitivity of culture for Aspergillus spp. from clinical 
specimens (19). If Aspergillus is isolated from infected tissue, the 
measurement of fungal burden in the infected tissue is critical in 
the evaluation of the therapeutic response. As a reference meth-
od, the quantitative culture using the colony forming unit (CFU) 
counting has been utilized for various organisms including such 
fungal pathogens as Candida spp. and Cryptococcus neoformans. 
However, repeated sampling of the infected tissue by invasive 
Table 4. Cox regression analysis for the prediction of treatment failure at 12 weeks
Characteristics Hazard ratio (95% CI) P
Age
    ≤ 60 yr old
    > 60 yr old
 
1.00
2.385 (0.477-11.934)
 
 
0.290
Sex
   Female 
   Male
 
1.00
3.568 (0.718-17.736)
 
 
0.120
Treatment of hematologic disease
   Chemotherapy
   Hematopoietic stem cell transplantation
   Conservative treatment
 
1.00
0.766 (0.148-3.961)
0.567 (0.051-6.265)
 
 
0.751
0.643
Status of hematologic disease
   Complete remission
   Nonremission
 
1.00
5.349 (1.074-26.646)
 
 
0.041
Organ of invasive aspergillosis
   Pulmonary
   Extrapulmonary
 
1.00
0.035 (0.000-57.069)
 
 
0.374
NASBA outcome
   Success
   Failure
 
1.00
5.235 (1.246-21.999)
 
 
0.024
NASBA, nucleic acid sequence-based amplification.
Fig. 1. Cumulative survival of the patients according to the nucleic acid sequence-
based amplification (NASBA) outcome.
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procedure may not be feasible in immunocompromised pa-
tients. Furthermore, CFU counting may not accurately estimate 
the burden of filamentous fungi, such as Aspergillus spp., be-
cause of their characteristic growth patterns (20). Several inves-
tigators have attempted to measure the fungal burden using non-
culture-based methods for Aspergillus spp. It has been shown 
that GM-EIA, (1→3)-β-D-glucan, quantitative PCR, and NASBA 
were available alternatives to the quantitative culture (21-24). 
Recently, the kinetics of GM-EIA has been reported as a predic-
tive tool either for assessing the prognosis or for the surrogate 
marker for the treatment endpoint of IA (25-27). There has been 
a report showing that the tendency for persistently positive PCR 
was related to a poor prognosis of IA (28). The marker-guided 
approach could have several advantages, as follows: 1) proper 
modification of the antifungal therapy at the appropriate time, 
2) determination of the optimal duration of the antifungal ther-
apy, 3) minimization of the antifungal drug use and reduction 
of both the toxicity and the cost related to antifungal therapy.
  Nucleic acid-based amplification assays, including PCR and 
NASBA, require numerous precautions to minimize false-posi-
tive results due to previously amplified products or environmen-
tal presence of fungal spores or DNA (29). To date, most studies 
using nucleic acid-detection tests have been focused primarily 
on standardization and validation of the accurate and early diag-
nosis of IA (10, 11, 30). In this study, the patients without nega-
tive conversion of Aspergillus mRNA, even at the end of the clin-
ical course, showed a tendency for higher peak values of NASBA. 
The duration of the persistently positive NASBA was longer in 
these patients, although the differences were not statistically sig-
nificant. There was a significant association between the NASBA 
and the clinical outcome at 12 weeks, not at 6 weeks (data not 
shown). The reason for this difference was possibly that the ad-
ministration of antifungal agents with known increased activity 
on Aspergillus spp., such as voriconazole, was delayed as salvage Kim S-H, et al.  •  RTi-NASBA and Clinical Outcome of IA
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therapy in most patients. This is attributed to the limitation of 
the national health insurance system of Korea. Ultimately, supe-
rior survival in the NASBA success group implied a significant 
impact of IA on mortality of immunocompromised patients.
  Our study had several limitations. We investigated a relatively 
small number of patients, and the sampling intervals for NASBA 
were not uniform because data was retrospectively collected. 
This study included possible cases of IA that could impact on the 
results. Nevertheless, to the best of our knowledge, this is the 
first report showing that patients with the persistently positive 
NASBA at the end of the clinical course were significantly asso-
ciated with both treatment failure and death attributable to IA. 
We consider that our findings have to be complemented by the 
well-designed future studies performed on a larger scale.
  In conclusion, the serial monitoring of RTi-NASBA correlated 
well with the clinical outcome of IA in patients with hematolog-
ic diseases during the antifungal treatment. It is suggested that 
the RTi-NASBA can be used as a useful marker to predict the 
treatment response and clinical outcome of IA. 
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